Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note released on Monday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Several other analysts also recently issued reports on RVNC. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. Barclays reaffirmed an “equal weight” rating and set a $7.00 target price (down previously from $10.00) on shares of Revance Therapeutics in a research report on Friday, September 13th. Piper Sandler lowered shares of Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 12th. HC Wainwright reaffirmed a “neutral” rating and set a $6.60 price objective on shares of Revance Therapeutics in a report on Friday, November 8th. Finally, Guggenheim reiterated a “neutral” rating on shares of Revance Therapeutics in a report on Monday, August 12th. Nine research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, Revance Therapeutics presently has a consensus rating of “Hold” and an average price target of $9.66.

Revance Therapeutics Stock Performance

NASDAQ:RVNC opened at $3.99 on Monday. The company has a market capitalization of $418.56 million, a P/E ratio of -2.16 and a beta of 0.95. The stock’s 50 day moving average price is $5.41 and its 200 day moving average price is $4.45. Revance Therapeutics has a 52 week low of $2.30 and a 52 week high of $9.74.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The firm had revenue of $59.88 million for the quarter, compared to analyst estimates of $67.73 million. As a group, sell-side analysts forecast that Revance Therapeutics will post -1.54 earnings per share for the current fiscal year.

Institutional Trading of Revance Therapeutics

A number of hedge funds have recently bought and sold shares of RVNC. Certuity LLC acquired a new position in shares of Revance Therapeutics during the second quarter valued at about $26,000. FORA Capital LLC bought a new position in Revance Therapeutics during the third quarter valued at about $54,000. Creative Planning acquired a new position in Revance Therapeutics in the 3rd quarter valued at approximately $56,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Revance Therapeutics during the 2nd quarter worth approximately $33,000. Finally, Accredited Investors Inc. acquired a new position in shares of Revance Therapeutics in the third quarter valued at $67,000. 97.70% of the stock is owned by institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.